Drugs targeting Bcl-2 family members as an emerging strategy in cancer

Bcl-2 family members: Dual regulators of apoptosis and autophagy

(2014) Beth Levine et al.   Autophagy

Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia

(2012) Manlio Tolomeo et al.   Anti-Cancer Agents in Medicinal Chemistry

Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance

(2010) Laura Bonapace et al.   JOURNAL OF CLINICAL INVESTIGATION

The landscape of somatic copy-number alteration across human cancers

(2010) Rameen Beroukhim et al.   NATURE

Bcl-2 family on guard at the ER

(2009) Eva Szegezdi et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Different forms of cell death induced by putative BCL2 inhibitors

(2009) M Vogler et al.   CELL DEATH AND DIFFERENTIATION

Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy

(2009) M. H. Kang et al.   CLINICAL CANCER RESEARCH

The Double-Edged Sword of Autophagy Modulation in Cancer

(2009) E. White et al.   CLINICAL CANCER RESEARCH

Antagonism of Beclin 1-dependent autophagy by BCL-2 at the endoplasmic reticulum requires NAF-1

(2009) Natasha C Chang et al.   EMBO JOURNAL

The role of autophagy in tumour development and cancer therapy

(2009) Mathias T. Rosenfeldt et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Novel Bcl-2 Homology-3 Domain-like Sequences Identified from Screening Randomized Peptide Libraries for Inhibitors of the Pro-survival Bcl-2 Proteins

(2009) Erinna F. Lee et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Conformational Changes in Bcl-2 Pro-survival Proteins Determine Their Capacity to Bind Ligands

(2009) Erinna F. Lee et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Control of mitochondrial apoptosis by the Bcl-2 family

(2009) J. K. Brunelle et al.   JOURNAL OF CELL SCIENCE

Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells

(2009) Cristian Bellodi et al.   JOURNAL OF CLINICAL INVESTIGATION

5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen

(2009) Susan O'Brien et al.   JOURNAL OF CLINICAL ONCOLOGY

Why Do Tumors Become Resistant to Antiangiogenesis Drugs?

(2009) Charlie Schmidt   JNCI-Journal of the National Cancer Institute

Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737

(2009) P. Hauck et al.   MOLECULAR CANCER THERAPEUTICS

BAX Inhibitor-1 Is a Negative Regulator of the ER Stress Sensor IRE1α

(2009) Fernanda Lisbona et al.   MOLECULAR CELL

Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival

(2009) Martin Schwickart et al.   NATURE

The autophagy effector Beclin 1: a novel BH3-only protein

(2009) S Sinha et al.   ONCOGENE

BH3-only proteins and their roles in programmed cell death

(2009) M Giam et al.   ONCOGENE

Correlation signature of the macroscopic states of the gene regulatory network in cancer

(2009) N. Slavov et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor

(2008) Yi-Ping Rong et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors

(2008) K. F. Whitecross et al.   BLOOD

Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia

(2008) S. M. O'Brien et al.   BLOOD

Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma

(2008) Barbara Pro et al.   BRITISH JOURNAL OF HAEMATOLOGY

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

Oncogene Addiction versus Oncogene Amnesia: Perhaps More than Just a Bad Habit?

(2008) D. W. Felsher et al.   CANCER RESEARCH

Membrane Binding by tBid Initiates an Ordered Series of Events Culminating in Membrane Permeabilization by Bax

(2008) Jonathan F. Lovell et al.   CELL

A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies

(2008) A. D. Schimmer et al.   CLINICAL CANCER RESEARCH

Autophagosome formation from membrane compartments enriched in phosphatidylinositol 3-phosphate and dynamically connected to the endoplasmic reticulum

(2008) Elizabeth L. Axe et al.   JOURNAL OF CELL BIOLOGY

BAX activation is initiated at a novel interaction site

(2008) Evripidis Gavathiotis et al.   NATURE

Essential role for Nix in autophagic maturation of erythroid cells

(2008) Hector Sandoval et al.   NATURE

Bcl-XL Inhibits Membrane Permeabilization by Competing with Bax

(2008) Lieven P Billen et al.   PLOS BIOLOGY

The BCL-2 protein family: opposing activities that mediate cell death

(2007) Richard J. Youle et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY